Skip to main content
. 2020 Nov 19;10(11):974. doi: 10.3390/diagnostics10110974

Table 1.

Spearman correlation coefficients and p-values of the correlations of BMI and laboratory parameters and chemerin in the whole cohort before direct-acting antiviral (DAA) therapy, at 4 and 12 weeks after start of therapy and 3 months after the end of therapy. Significant correlations are in bold.

Parameter Baseline
(82 patients)
4 weeks
(79 patients)
12 weeks
(81 patients)
3 Months after End of Therapy
(71 patients)
BMI kg/m2 0.046 (0.695) 0.028 (0.816) 0.054 (0.653) −0.002 (0.987)
MELD Score −0.777 (<0.001) −0.749 (<0.001) −0.752 (<0.001) −0.578 (<0.001)
ALT U/L 0.119 (0.286) −0.067 (0.559) −0.057 (0.612) 0.198 (0.104)
AST U/L −0.233 (0.035) −0.379 (0.001) −0.500 (<0.001) −0.475 (<0.002)
Bilirubin mg/dL −0.588 (<0.001) −0.614 (<0.001) −0.668 (<0.001) −0.591 (<0.001)
Albumin g/L 0.592 (<0.001) 0.453 (<0.001) 0.537 (<0.001) 0.220 (0.071)
INR −0.815 (<0.001) −0.744 (<0.001) −0.786 (<0.001) −0.815 (<0.001)
Creatinine mg/dL 0.099 (0.378) 0.000 (0.997) 0.111 (0.325) 0.165 (0.175)
Leukocytes n/L 0.628 (<0.001) 0.515 (<0.001) 0.572 (<0.001) 0.360 (0.003)
CRP mg/L 0.003 (0.979) 0.079 (0.489) −0.103 (0.362) 0.199 (0.101)
HDL mg/dL 0.021 (0.857) 0.123 (0.292) 0.129 (0.261) 0.005 (0.971)
LDL mg/dL 0.598 (<0.001) 0.655 (<0.001) 0.681 (<0.001) 0.618 (<0.001)

Alanine amino transferase, ALT; aspartate aminotransferase, AST; C-reactive protein, CRP; MELD, model of end-stage liver disease; INR, international normalized ratio; LDL, low-density lipoprotein; HDL, high-density lipoprotein.